Pharma Partnering

Know which pharma to approach, and with what

Sleuth maps the top 25 pharma’s pipelines by franchise, matches your best program to where each one is thin, and lists the proof each will ask for, so you can tailor every pitch.

Free to try on your own platform

The analysis

Who to approach first, what to lead with, and what to bring

What is each pharma building?

Each pharma’s programs, deals, and stated priorities, franchise by franchise, with the platforms it already owns or licenses.

Where does our platform fit them?

What your platform could lead with, matched to each franchise and ranked on cited evidence. Sleuth sets aside any fit that depends on data you don’t have yet.

Who already has something like us?

The pharma that own or license a competing platform, ranked lower with the reason, so you don’t pitch a company that’s building it in house.

What will each one ask before a meeting?

For each priority pharma, the case for and against, the objections to expect, the proof to have in hand, and the events to watch before your meeting.

Describe your platform, and Sleuth lines up the pharma

Step 1

Describe your platform

Say what your platform has and hasn’t shown, the decision you face, such as which pharma to meet at a conference coming up, and where you want to focus.

Step 2

Decide what counts

Choose what makes a good partner for you, such as fit with a franchise, deal record, and whether it already owns a competing platform, and how much each one counts.

Step 3

Shape the plan

See the three steps Sleuth will run: map the pipelines, match your programs and rank the pharma, and prepare each outreach. Add a company or drop one before it runs.

Step 4

Get the analysis

A ranked list of pharma, with what to lead with and what to bring for each, and the program matches as a dataset.

Which pharma should an immune-cell RNA platform approach first? Sleuth says Biogen.

A fictional platform, matched to the top 25 pharma before a March partnering conference. Given the same question, a general AI model left Biogen out.

Pharma Partnering: immune-cell RNA platform

Pharma Partnering: immune-cell RNA platform: Approach five pharma first with B-cell siRNA in immunology, starting with Biogen.
Case Study

How one of the largest diagnostics companies reaches drug developers before they pick a partner

Its team used to take one value proposition to every pharma partner. Studio mapped every program in four newer kinds of cancer drug, the test each relies on, and who supplies it, so the team now reaches each sponsor before it chooses a diagnostic partner.

ADCs

ADCs

747 programs in four newer kinds of cancer drug, one mark per program: ADCs, bispecifics and T-cell engagers, cell therapies, and radiopharmaceuticals. Source: Sleuth analysis for an oncology diagnostics company.

Does it work before we have clinical data?

Yes. The example platform is preclinical. Sleuth sets aside any fit that depends on data you don’t have yet, and lists the proof to get first.

Can I add a pharma that isn’t in the top 25?

Yes. Add it when you shape the plan, and Sleuth maps it the same way.

Can I prepare for one meeting instead of five?

Yes. Name the company, and Sleuth builds its case for and against, the objections to expect, and the proof to bring.

How does Sleuth know what each pharma wants?

From each pharma’s programs, deals, and stated priorities, read franchise by franchise, with the source behind each one.

Why is a pharma ranked lower?

Sleuth gives the reason beside it, such as owning a competing platform, or a fit that depends on data you don’t have yet.

Line up the pharma for your platform

Set up in Claude, ChatGPT, or Copilot